[go: up one dir, main page]

IN2012DN02861A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02861A
IN2012DN02861A IN2861DEN2012A IN2012DN02861A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A IN 2861DEN2012 A IN2861DEN2012 A IN 2861DEN2012A IN 2012DN02861 A IN2012DN02861 A IN 2012DN02861A
Authority
IN
India
Prior art keywords
relates
pharmaceutical compositions
compositions
igf
insulin
Prior art date
Application number
Inventor
Enona Gopinath
Susan Park
Tsutomu Arakawa
Joel Richard
Fabio Fais
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of IN2012DN02861A publication Critical patent/IN2012DN02861A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions. More particularly, the invention relates to formulations of growth hormone (GH) and insulin-like growth factor (IGF-1) combination compositions which provide stable pharmaceutical compositions without aggregation formation at a desirable pH, and to processes of preparation thereof.
IN2861DEN2012 2009-11-17 2010-11-17 IN2012DN02861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26185909P 2009-11-17 2009-11-17
PCT/EP2010/006996 WO2011060922A1 (en) 2009-11-17 2010-11-17 Formulation for hgh and rhigf-1 combination

Publications (1)

Publication Number Publication Date
IN2012DN02861A true IN2012DN02861A (en) 2015-07-24

Family

ID=43661042

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2861DEN2012 IN2012DN02861A (en) 2009-11-17 2010-11-17

Country Status (14)

Country Link
US (2) US20120270782A1 (en)
EP (1) EP2501367B1 (en)
JP (2) JP6084036B2 (en)
KR (1) KR101614983B1 (en)
CN (1) CN102665691B (en)
AU (1) AU2010321225B2 (en)
BR (1) BR112012011539A8 (en)
CA (1) CA2780554C (en)
ES (1) ES2532007T3 (en)
IN (1) IN2012DN02861A (en)
MX (1) MX2012005195A (en)
RU (1) RU2558821C2 (en)
UA (1) UA108994C2 (en)
WO (1) WO2011060922A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1901770B1 (en) 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
BR112014001921B1 (en) 2011-07-25 2022-05-10 Sandoz Ag Pharmaceutically acceptable aqueous formulation, method of increasing the stability of a pharmaceutically acceptable aqueous formulation and main packaging
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
CN104371019B (en) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1
EP3209332B1 (en) 2014-10-23 2021-05-26 Amgen Inc. Reducing viscosity of pharmaceutical formulations
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
EP3257524B1 (en) * 2015-02-11 2020-08-26 Gmax Biopharm LLC Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
WO2017180594A1 (en) * 2016-04-13 2017-10-19 Medimmune, Llc Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
US20210087236A1 (en) * 2016-08-15 2021-03-25 The University Of North Carolina At Chapel Hill Tardigrade disordered proteins as protein stabilizers
US11459401B2 (en) 2016-10-06 2022-10-04 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
US10953074B2 (en) * 2017-01-08 2021-03-23 Richard D. Lippman Composition and method for improving sensorineural hearing
JP7377596B2 (en) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド Low viscosity, high concentration evolocumab formulations and their manufacturing method
CA3176341A1 (en) * 2020-04-22 2021-10-28 Zyon AYNI Pharmaceutical compositions and anti-viral uses thereof
JP2023550203A (en) * 2020-10-19 2023-11-30 オーク ヒル バイオ リミテッド Compositions suitable for use in neonates
JP2024507778A (en) * 2021-02-12 2024-02-21 ニューレン ファーマシューティカルズ リミテッド Treatment of Prader-Willi syndrome
AU2022399020A1 (en) * 2021-11-26 2024-06-13 Genexine, Inc. High concentration administration formulation of hgh fusion protein

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology
WO1994003198A1 (en) * 1992-07-31 1994-02-17 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
SE9201073D0 (en) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab PROTEIN FORMULATION
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
JPH10511964A (en) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ Stabilized pharmaceutical preparation containing growth hormone and X-Lys
JP2001522813A (en) * 1997-11-07 2001-11-20 カイロン コーポレイション Novel IGF-I Compositions and Uses Thereof
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
KR20020031388A (en) * 1999-07-12 2002-05-01 그란디스 비오테크 게엠베하 Growth Hormone Formulations
CN1245216C (en) * 1999-10-04 2006-03-15 希龙公司 Stabilized polypeptide-containing liquid pharmaceutical composition
PT1478394E (en) * 2002-02-27 2008-10-08 Immunex Corp Stabilized tnfr-fc composition comprising arginine
MXPA05000412A (en) * 2002-07-09 2005-07-22 Sandoz Ag Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine.
EP1901770B1 (en) 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
HUE033949T2 (en) * 2005-11-01 2018-01-29 Wyeth Llc Sodium chloride solution for drug reconstitution or dilution
ES2605022T3 (en) * 2006-07-06 2017-03-10 Daewoong Co., Ltd. A stable liquid formulation of human growth hormone
WO2009136568A1 (en) * 2008-05-08 2009-11-12 味の素株式会社 Protein reforming method

Also Published As

Publication number Publication date
RU2558821C2 (en) 2015-08-10
JP2013510893A (en) 2013-03-28
KR101614983B1 (en) 2016-04-22
BR112012011539A8 (en) 2017-12-26
HK1175711A1 (en) 2013-07-12
MX2012005195A (en) 2012-06-12
EP2501367B1 (en) 2015-01-21
WO2011060922A1 (en) 2011-05-26
KR20120104251A (en) 2012-09-20
CN102665691A (en) 2012-09-12
ES2532007T3 (en) 2015-03-23
CN102665691B (en) 2015-05-27
UA108994C2 (en) 2015-07-10
RU2012124985A (en) 2013-12-27
AU2010321225B2 (en) 2015-12-03
AU2010321225A1 (en) 2012-06-07
EP2501367A1 (en) 2012-09-26
CA2780554A1 (en) 2011-05-26
JP2016020395A (en) 2016-02-04
US20170143834A1 (en) 2017-05-25
CA2780554C (en) 2017-08-15
US20120270782A1 (en) 2012-10-25
JP6143827B2 (en) 2017-06-07
JP6084036B2 (en) 2017-02-22
BR112012011539A2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
IN2012DN02861A (en)
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
EP3626253A3 (en) Stable formulations of linaclotide
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2010079468A3 (en) Delivery particle
WO2010084480A3 (en) Delivery particles
WO2010079467A3 (en) Delivery particles
WO2010079466A3 (en) Delivery particles
PL2081547T3 (en) Galenic form for the trans-mucosal delivery of active ingredients
MX2011012122A (en) Thiophene derivatives.
MY153976A (en) Lh liquid formulations
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
WO2010092090A3 (en) Novel salts of sitagliptin
EP2431366A4 (en) New chlorine e6-folic acid conjugated compound, preparation method thereof, and pharmaceutical composition containing the same for treatment of cancer
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
IN2012DN01292A (en)
WO2007113202A8 (en) Piperazine derivatives as growth hormone secretagogue (ghs) receptor agonists
WO2012128582A3 (en) A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
MX2009007265A (en) Salts, aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation.
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
MX2011007736A (en) Stable growth hormone compounds.
MX2013009459A (en) Pharmaceutical preparation containing selenite or selenite-containing compounds for treating cervical dysplasia or carcinomas.
WO2012029074A3 (en) Pharmaceutical compositions of linezolid
WO2008066729A3 (en) Boronic acid containing compositions